Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Apr;40(2):100857.
doi: 10.1016/j.accpm.2021.100857. Epub 2021 Mar 30.

Anticoagulation in COVID-19: not strong for too long?

Charles Tacquard  1 , Alexandre Mansour  2 , Alexandre Godon  3 , Yves Gruel  4 , Sophie Susen  5 , Anne Godier  6 , Pierre Albaladejo  3
Affiliations
Editorial

Anticoagulation in COVID-19: not strong for too long?

Charles Tacquard et al. Anaesth Crit Care Pain Med. 2021 Apr.
No abstract available

Keywords: Anticoagulation; Bleeding; COVID-19; Complications; Thrombosis.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Distribution of medians and interquartile ranges for duration between admission (hospital/ICU) and events (thrombosis in blue, bleeding in red) based on selected studies. For each study, details on the type and location of recorded events and the number of events/number of patients included are shown in the right-hand column. (B) Results of the meta-analysis using a quantile estimation method. Data are expressed as median and interquartile range. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article). *For these two studies, the data are expressed as a mean (standard deviation). These studies were excluded from further analysis in B.
See this image and copyright information in PMC

References

    1. Investigators I., Sadeghipour P., Talasaz A.H., Rashidi F., Sharif-Kashani B., Beigmohammadi M.T. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the inspiration randomized clinical trial. JAMA. 2021;18 doi: 10.1001/jama.2021.4152. - DOI - PMC - PubMed
    1. Network C-IGobotR, the C-ICUI Clinical characteristics and day-90 outcomes of 4244 critically ill adults with COVID-19: a prospective cohort study. Intensive Care Med. 2021;47(1):60–73. - PMC - PubMed
    1. Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., Muller M.C.A. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002. - PMC - PubMed
    1. Suh Y.J., Hong H., Ohana M., Bompard F., Revel M.P., Valle C. Pulmonary embolism and deep vein thrombosis in COVID-19: a systematic review and meta-analysis. Radiology. 2020 - PMC - PubMed
    1. Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–1099. - PMC - PubMed

Publication types